217 128

Cited 3 times in

Clinical factors associated with response or survival after chemotherapy in patients with Waldenström macroglobulinemia in Korea

Authors
 Ho Sup Lee  ;  Kihyun Kim  ;  Dok Hyun Yoon  ;  Jin Seok Kim  ;  Soo-Mee Bang  ;  Jeong-Ok Lee  ;  Hyeon Seok Eom  ;  Hyewon Lee  ;  Inho Kim  ;  Won Sik Lee  ;  Sung Hwa Bae  ;  Se Hyung Kim  ;  Mark Hong Lee  ;  Young Rok Do  ;  Jae Hoon Lee  ;  Junshik Hong  ;  Ho-Jin Shin  ;  Ji Hyun Lee  ;  Yeung-Chul Mun  ;  Chang-Ki Min 
Citation
 BIOMED RESEARCH INTERNATIONAL, Vol.2014 : 253243, 2014 
Journal Title
 BIOMED RESEARCH INTERNATIONAL 
ISSN
 2314-6133 
Issue Date
2014
MeSH
Adult ; Aged ; Aged, 80 and over ; Female ; Humans ; Male ; Middle Aged ; Prognosis* ; Republic of Korea ; Retrospective Studies ; Survival Analysis* ; Treatment Outcome ; Waldenstrom Macroglobulinemia/drug therapy* ; Waldenstrom Macroglobulinemia/epidemiology ; Waldenstrom Macroglobulinemia/pathology
Abstract
Waldenström's macroglobulinemia (WM) is a B-cell proliferative malignancy characterized by immunoglobulin M monoclonal gammopathy and bone marrow infiltration by lymphoplasmacytic cells. Clinical features and cytogenetics of WM in Asia including Republic of Korea remain unclear. Moreover, no study has reported treatment outcomes in patients with WM treated with novel agent combined with conventional chemotherapy. This study investigated clinical features and assessed treatment outcomes with novel agent and conventional chemotherapy in Republic of Korea. Data from all (n = 71) patients with newly diagnosed WM at 17 hospitals who received chemotherapy between January 2005 and December 2012 were collected retrospectively. The median age of patients was 66 years (range: 37-92 years) and male to female ratio was 5 : 1. Patients treated with novel agent combined chemotherapy displayed higher overall response rate (ORR) compared to conventional chemotherapy alone (92.9% versus 52.6%, P = 0.006). The 5-year overall survival rate was 62.6% (95% confidence interval: 34.73-111.07). Use of novel agents produced higher ORR but survival benefit was not apparent due to the small number of patients and short follow-up duration. Further studies are needed to confirm the efficacy of novel agents in patients with WM.
Files in This Item:
T201405634.pdf Download
DOI
10.1155/2014/253243
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Jin Seok(김진석) ORCID logo https://orcid.org/0000-0001-8986-8436
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/138803
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse